 |
Previous Article | Next Article 
The Journal of Neuroscience, September 15, 2001, 21(18):7037-7045
SP Proteins and PHOX2B Regulate the Expression of the Human
PHOX2a Gene
Adriano
Flora1,
Helen
Lucchetti1,
Roberta
Benfante1,
Christo
Goridis2,
Francesco
Clementi1, and
Diego
Fornasari1
1 Department of Medical Pharmacology, University of
Milan and Consiglio Nazionale delle Ricerche Cellular and Molecular
Pharmacology Center, 20129 Milan, Italy, and 2 Laboratoire
de Génétique et Physiologie du Développement,
Institut de Biologie du Développement de Marseille, Centre
National de la Recherche Scientifique /Institut National de la
Santé et de la Recherche Médicale/Université de la
Méditeranée, Marseille, France 13288
 |
ABSTRACT |
Phox2a is a vertebrate homeodomain transcription factor that is
involved in the specification of the autonomic nervous system. We have
isolated the 5' regulatory region of the human Phox2a gene and studied the transcriptional mechanisms underlying its expression. We first identified the minimal gene promoter by means of
molecular and functional criteria and demonstrated that its activity
relies on a degenerate TATA box and a canonical Sp1 site. We then
concentrated on the region immediately upstream of the promoter and
found that it stimulates transcription in a neurospecific manner
because its deletion caused a substantial decline in reporter gene
expression only in neuronal cells. This DNA region contains a putative
binding site for homeodomain transcription factors, and its mutation
severely affects the transcriptional activity of the entire 5'
regulatory region, thus indicating that this site is necessary for the
expression of Phox2a in this cellular context. The use
of the electrophoretic mobility shift assay showed that
Phox2b/PMX2b is capable of specifically interacting with this site, and
cotransfection experiments demonstrated that it is capable of
transactivating the human Phox2a promoter. Many data
obtained from knock-out mice support the hypothesis that Phox2a acts
downstream of Phox2b during the development of most of the autonomic
nervous system. We have provided the first molecular evidence that
Phox2b can regulate the expression of Phox2a by directly
binding to its 5' regulatory region.
Key words:
human; transcription factors; autonomic nervous system; transcriptional regulation; homeoproteins; promoter
 |
INTRODUCTION |
One of the central issues in modern
neurobiology is to understand how neuronal cell fate is determined. The
neural crest is the cell type that has provided the most detailed
information concerning the mechanisms controlling the fate of
multipotential neural progenitors (Anderson, 1997 ; Francis, 1999 ), and,
over the past few years, many aspects of the developmental program culminating in the formation of the autonomic nervous system have been
elucidated. These studies have indicated the central role of two highly
homologous transcription factors, Phox2a and Phox2b (also known as
ARIX/PMX2A and PMX2b, respectively).
Phox2a and Phox2b are homeodomain proteins that are precociously and
very similarly expressed in the three peripheral divisions of the
autonomic nervous system (Valarché et al., 1993 ; Tiveron et al.,
1996 ; Pattyn et al., 1997 ). They are also expressed in all of the
adrenergic and noradrenergic neurons of the brainstem, in some cranial
sensory ganglia that participate in the autonomic reflexes, and in a
subset of cranial motor neurons. All of the components of the autonomic
nervous system fail to properly develop in Phox2b knock-out (KO) mice,
whereas Phox2a null mutants show a less severe phenotype involving the
agenesis of the locus coeruleus and the atrophy of cranial
sensory ganglia (Morin et al., 1997 ; Hirsch et al., 1998 ; Pattyn et
al., 1999 ). These and other in vivo studies have also
demonstrated that, with the exception of the cranial sensory ganglia,
Phox2a acts downstream of Phox2b and Mash1, a basic helix-loop-helix
transcription factor that has been shown to promote competence for
neurogenesis in neural crest progenitors (Lo et al., 1997 , 1998 ; Stanke
et al., 1999 ). Together with Phox2b, Phox2a seems to act upstream of
Ret [a subunit of the glia-derived neurotrophic factor receptor
required for the survival of aggregating sympathoblasts (Durbec et al.,
1996 ) and migrating enteric neuroblasts (Young et al., 1998 )], and
dopamine- -hydroxylase, the last enzyme in the noradrenaline
synthesis pathway (Zellmer et al., 1995 ; Goridis and Brunet, 1999 ).
Although these data suggest that Phox2a is probably involved in both
the specification of autonomic phenotypes and the terminal differentiation of sympathetic neurons, most of its functional role is
still enigmatic: it is expressed in all of the ganglionic neurons of
the peripheral autonomic nervous system but appears to be necessary for
the appropriate development of only a subset of sympathetic and
parasympathetic ganglia (Morin et al., 1997 ). A better understanding of
the transcriptional mechanisms underlying the expression of Phox2a and
the molecular definition of the regulatory circuits that link it with
Mash1 and Phox2b may provide new insights into its role. To this end,
we cloned the 5' regulatory region of the human Phox2a gene
and characterized some of its molecular and functional properties.
 |
MATERIALS AND METHODS |
RNA preparation and Northern blot analysis. The RNAs
were prepared and the Northern blot analysis performed as described in Flora et al. (2000) . The RNAs were hybridized with a mouse
ApaI-ApaI cDNA probe spanning from nucleotide
687 to nucleotide 1218 of the published sequence, corresponding to the
C terminus and part of the 3' UTR of Phox2a (Valarché et
al., 1993 ) (GenBank accession number X75014).
Molecular cloning of the human Phox2a 5'-flanking region. A
human Phox2a cDNA probe was obtained from the SY5Y human neuroblastoma cell line by means of RT-PCR using primers designed on the first exon.
The upper primer was 5'-CGGGCGCTCAGAGCTGGCCTCG-3' [nucleotide (nt)
+51/+72; see Fig. 2B]; the lower primer was
5'-CATGGCCGCCACGCACGAGTCG-3' (nt +219/+198 on the lower strand; see
Fig. 2B). The expected 168 bp fragment obtained was
completely sequenced on both strands and used to screen a commercial
human genomic library (Clontech, Palo Alto, CA) from normal peripheral
blood leukocytes, cloned in the vector EMBL3 SP6/T7. After three
rounds of screening, we isolated six different clones, one of which was
analyzed in detail, by means of restriction analysis and the sequencing
of both strands.
Primer extension. Total RNA from SY5Y cells expressing and
HeLa cells not expressing Phox2a mRNA (see Fig. 1) was used to perform
primer extension experiments.
The experiments were performed using a
32P-labeled oligonucleotide
(5'-GTACGAATTGAGGTAGGAGTAGTCCATCGGCCC-3') complementary to the human
Phox2a ATG surrounding sequence [ nt +166/+198; underlined in Fig. 2B]. Briefly, an amount of oligonucleotide
corresponding to 5 × 105 cpm was
coprecipitated with 20 µg of total RNA and elongated with 200 U
Superscript II (BRL-Life Technologies, Gaithersburg, MD) at
50°C for 90 min. Yeast RNA was also elongated as a negative control.
The reaction products were run on a 6% polyacrylamide denaturing gel.
A DNA sequence was run in parallel as a molecular marker.
Construction of the human Phox2a promoter reporter plasmids.
All of the reporter constructs were obtained by subcloning fragments of
the human Phox2a 5'-flanking region into the pGL3basic plasmid (Promega, Madison, WI) upstream of the Firefly luciferase
gene. A PstI-PstI genomic fragment (see Fig.
2A) was first subcloned in pBluescript II KS and
completely sequenced on both strands. From this construct we isolated
the SacI-NcoI region containing the first 48 nt
of the human Phox2a coding sequence and the entire 5' UTR (see Fig.
2A) and subcloned this fragment in pGL3basic to
obtain the SacI/NcoI construct in which
the sequence encoding the first 16 amino acids of Phox2a was fused in
frame with the coding sequence of the luciferase enzyme (see Fig.
4A). To generate the PstI/NcoI
construct, we digested the PstI-PstI fragment
cloned in pBluescript II KS with SacI, the sites of which
were located in the Phox2a 5'-flanking sequence (see Fig. 2) and in the
polylinker of the vector. The resulting 1140bp
SacI-SacI fragment was gel-purified and
subcloned in the SacI site of the
SacI/NcoI construct in the proper orientation.
PstI/EagI was created by digesting the
PstI-PstI fragment cloned in pBluescript II KS
with EagI, the sites of which were located in the Phox2a
5'-flanking sequence (see Fig. 2) and in the polylinker of the vector;
the resulting fragment was blunt ended and subcloned in the
SmaI site of pGL3basic, upstream of the luciferase 5' UTR
(see Fig. 4A). StuI/NcoI was
obtained by digesting PstI/NcoI with
PstI and StuI, blunting, and religating. SacI/EagI was derived from the
PstI/EagI construct using the same cloning
strategy. SV40 has already been described (Flora et al., 2000 ). The
pRL-TK plasmid was purchased from Promega.
To introduce point mutations into the putative TATA box, Sp1 site, and
homeoprotein binding site (hbs) (see Fig. 2, hbs), we
exploited the recombinant PCR technique (Higuchi, 1990 ) using the
PstI/NcoI construct as a template. Briefly, two
complementary oligonucleotides bearing mutations in the core sequence
of the putative DNA binding site of interest were used independently in
separate amplification reactions, together with external primers corresponding to plasmid sequences. The two amplification products were
then mixed together, denatured, and subjected to 10 extension cycles.
The resulting DNA was subsequently amplified with the external primers,
digested with the appropriate restriction enzymes, subcloned in
pGL3basic, and sequenced. The Pfx thermostable DNA polymerase (BRL-Life Technologies) was used in all of the
amplification steps. The derived constructs were named
PstI/NcoI TATAmut,
PstI/NcoI Sp1mut, PstI/NcoI
Sp1/TATAmut (when both mutations were present simultaneously), and
PstI/NcoI hbsmut. The oligonucleotides
(corresponding to nucleotides 65/ 43) used to mutate
the Sp1 site were Sp1mut UP
(5'-CGCCCCGAACCGAACCCCTCCGC-3') as upper
primer and Sp1 mut LOW
(5'-GGAGGGGTTCGGTTCGGGGCGAGCT-3') as lower primer.
The oligonucleotides (corresponding to nucleotides 40/ 14)
used to mutate the TATA box were TATA mut UP
(5'-GGTCCTGCGCGTGCCAAGGCGCGCGG-3') as upper primer and
TATA mut LOW (5'-CCGCGCGCCTTGGCACGCGCAGGACC-3') as lower primer.
The oligonucleotides used to mutate the hbs site were hbsmut UP
(5'-TCAGAGCGAATTGACGGAACTTCTTCA-3', corresponding to nucleotides 363/ 337) as upper primer and hbsmut LOW
(5'-GTGTGAAGAAGTTCCGTCAATTCGCTCTGA-3', corresponding to
nucleotides 334/ 363) as lower primer.
PRS1 has been described by Yang et al. (1998) .
The letters in bold indicate the mutated nucleotides. All of the
oligonucleotides listed above were purchased from Life Technologies.
The external oligonucleotides used in the PCR reactions were the
Promega RV3 and GL2 primers designed on the pGL3basic vector.
The Phox2b expression construct was obtained by subcloning mouse Phox2b
cDNA (Pattyn et al., 1997 ) in the XhoI and EcoRI
sites of pCDNA3 (Invitrogen, Groningen, The Netherlands).
Transient transfections and luciferase assays. The
cells were transiently transfected by means of lipofection using 2 × 105 SY5Y cells or 4 × 104 HeLa cells. Briefly, the cells were
plated onto a well of a six-multiwell tissue culture plate (Falcon) the
day before the transfection. Forty femtomoles of the construct of
interest were mixed with an equimolar amount of pRL-TK and added to 1 µl of FUGENE 6 (Hoffman-La Roche, Basel, Switzerland). The
DNA-lipid mixture was added to the cells and incubated for 36 hr, when
luciferase activity was measured. The pRL-TK plasmid expresses the
Renilla luciferase reporter gene under the control of
the thymidine kinase minimal promoter and was cotransfected in each
sample to normalize transfection efficiency. In the cotransfection
experiments with Phox2b, 150 fmol of the Phox2b expression construct
was added to the reporter and pRL-TK plasmids and incubated with 2 µl
of FUGENE 6. Firefly and Renilla luciferase
activities were detected using the Dual Luciferase Reporter Assay
System (Promega). All of the transfections were performed in duplicate,
and each construct was tested in at least three independent experiments
using different batches of plasmid preparation. All of the plasmids
were purified using Qiagen (Hilden, Germany) columns. The transient
transfection data were analyzed as described previously (Battaglioli et
al., 1998 ).
In vitro DNA-protein interaction analyses. The nuclear
extracts were obtained as described in Terzano et al. (2000) . To
prepare the probes for footprinting experiments, the
StuI-NcoI fragment was subcloned in pGEM-5Z
(Promega) and digested with NcoI to label the bottom strand
or with SalI to label the top strand. After filling in with
32P- -dCTP, the DNA was digested with
SalI or NcoI. The excised fragments were run on a
5% nondenaturing polyacrylamide gel and gel purified. In each
footprinting reaction, 2 fmol of the probe (~20,000-30,000 cpm) were
coincubated with 45 µg of nuclear extracts. Each reaction was
performed in 50 µl containing 25 µl 2× binding buffer (1× binding
buffer: 20 mM HEPES, pH 7.9, 2 mM MgCl2, 4% Ficoll, 0.5 mM DTT), 2 µg double-stranded poly(dI-dC), and
100 mM final salt concentration (NaCl + KCl). The
nuclear extracts were preincubated on ice for 45 min and, after the
addition of the probe, further incubated for 60 min. DNaseI was diluted
in 1× binding buffer, 100 mM KCl, and 20 mM MgCl2 and used at a
concentration 0.1-0.6 U/µg DNA in the samples with BSA, and 5-15
U/µg DNA in the presence of the extract. The DNaseI treatment was
performed by adding 5 µl of DNaseI dilution to each reaction followed
by incubation at room temperature for 150 sec. Digestion was stopped by
adding 55 µl of Stop buffer 2× (1×: 100 mM
NaCl, 10 mM Tris-HCl, pH 8, 10 mM EDTA, pH 8, 0.5% SDS, 5 µg/ml proteinase
K). After 30' of incubation at 50°C, the DNA was phenol-chloroform
extracted, ethanol precipitated, resuspended in denaturing loading dye
(NaOH 0.1 M/formamide 1:2; 0.01% xylene cyanol),
and loaded on a denaturing 6% polyacrylamide gel. A sequence was run
in parallel to the reactions as a molecular weight marker.
All of the oligonucleotides used in the electrophoretic mobility shift
assay (EMSA) experiments were labeled by fill-in and purified on
a G25 Sephadex column (Boehringer Mannheim, Mannheim, Germany). With
the Sp1 oligonucleotide, we used the footprint binding buffer,
whereas the binding conditions for the hbs oligo were 12.5 mM HEPES, pH 7.9, 4 mM Tris-HCl, pH 7.9, 60 mM KCl, 1 mM EDTA, 4% Ficoll, and 1 mM DTT. Samples containing 10 µl of 2× binding buffer, 2 µg of double-stranded poly(dI-dC), 2 µg nuclear extract, and
H2O to 20 µl were preincubated on ice for 20 min, and then 1 fmol of probe (corresponding to 10,000-20,000 cpm) was
added. After a 40 min incubation, the reactions were loaded on a
nondenaturing 5% polyacrylamide gel and run in Tris-Borate-EDTA 0.5× at a constant voltage of 150 V. Competition and supershift experiments were performed by adding the specific oligonucleotide or
antibody to the reactions during the preincubation time. We used 0.1 and 1 pmol of cold oligonucleotides for the competition experiments. The oligonucleotides used in the EMSA experiments were the
following: Phox2a/Sp1 (5'-CATGGAGCTCGCCCCGCCCCGCCCCCCTCCGC-3', nucleotides 71 to 47); Phox2a/Sp1mut
(5'-CATGGAGCTCGCCCCGAACCGAACCCCTCCGC-3'); hbs
(5'-TCAGAGCGAATTGATTAAACTTCTTCA-3', nucleotides 363-337); hbsmut is
described above. The Sp1 and EGR oligonucleotides have been described
previously (Terzano et al., 2000 ). All of the oligonucleotides were
purchased from Life Technologies, and all of the antibodies were
purchased from Santa Cruz Biotechnology (Santa Cruz, CA).
 |
RESULTS |
Detection of Phox2a transcript in human neuroblastoma
cell lines
Neuroblastomas are pediatric tumors that are thought to arise from
migratory cells of the embryonal neural crest; several clonal cell
lines have been stabilized and have most of the features of the
autonomic neurons, such as the ability to express ganglionic-type nicotinic receptors (Gotti et al., 1997 ).
To demonstrate that the neuroblastoma cell lines were capable of
expressing Phox2a mRNA, we performed a Northern blot analysis. A unique
transcript of ~1.9 kb was observed in only the two human neuroblastoma cell lines, SY5Y and SK-N-BE, whereas no signal was
detectable in HeLa and MOLT4 cells, two non-neuronal human cell lines
of epithelial and lymphoid origin, respectively (Fig. 1).

View larger version (45K):
[in this window]
[in a new window]
|
Figure 1.
Northern blot analysis of the expression of the
human Phox2a gene in different human cell lines. A mouse
ApaI-ApaI cDNA probe, corresponding to
the C terminus and part of the 3' UTR of Phox2a, was hybridized to 10 µg of total RNA purified from the indicated cell lines.
Top, The cDNA identified a unique transcript in
neuroblastoma cell lines. Bottom, The hybridization
signals obtained using human cDNA for the ribosomal RNA 18S after
stripping of the Phox2a probe.
|
|
A very intense band was detected in all four lanes when the same blot
was rehybridized with a probe for the 18S ribosomal RNA (Fig.
1).
Structural and functional characterization of the human
Phox2a 5' regulatory region
To isolate the 5'-flanking region of the Phox2a gene,
we screened a human genomic library with a probe corresponding to part of the first exon. We identified six different clones, all of which
contained a 1411 bp PstI-PstI fragment that
included most of the first exon (from nucleotide +1 to nucleotide +253)
(Valarché et al., 1993 ) and 1158 bp of the upstream region of the
human Phox2a gene (Fig. 2).
Primer extension experiments were performed to map the initiation of
transcription. A single band was observed in the SY5Y cells, whereas,
as expected, no signal was detectable in HeLa cells and yeast RNAs
(Fig. 3). Remarkably, the first
transcribed nucleotide identified by these experiments corresponded to
the first nucleotide of the cDNA sequence described by Johnson et al.
(1996) .

View larger version (61K):
[in this window]
[in a new window]
|
Figure 2.
Structural features of the 5'-flanking region of
the human Phox2a gene. A, Schematic
representation of the PstI-PstI region
showing the relevant restriction sites. The striped box
indicates the DNA sequence specifying the 5' UTR of the mRNA; the
black region corresponds to the first part of the coding
sequence. The arrow indicates the transcription start
site. B, Sequence of the
PstI-NcoI fragment. The positions are
numbered from the transcription start site (indicated by the
arrow), as defined by primer extension. The nucleotides
in bold correspond to the human Phox2a coding sequence;
the shaded region indicates the DNA sequence specifying
the 5' UTR of the mRNA, and the underlined sequence
corresponds to the primer used in the primer extension experiments. The
putative TATA box and DNA binding sites for Sp1 and homeodomain
transcription factors (hbs, homeodomain binding site)
are boxed. The relevant restriction sites are indicated,
and their sequences are underlined.
|
|

View larger version (25K):
[in this window]
[in a new window]
|
Figure 3.
Primer extension mapping of the transcription
start site of the human Phox2a gene. A 32P
oligonucleotide complementary to the +166/+198 region of the human
Phox2a gene (see also Fig. 2B) was
annealed to total RNA from the indicated cell lines and then extended.
Yeast RNA (yRNA) was used as a negative control.
The arrow indicates the only detected band, the length
of which is also indicated (nt, nucleotide).
|
|
The presence of a unique initiation site suggested that transcription
had to be driven by a promoter containing a TATA box or an Initiator
element, or both. Consistently, computer-assisted analysis
showed that a degenerate TATA box was present at the canonical location
of 25 nucleotides from the transcription start site (Fig.
2A). Moreover, a putative Sp1 binding site was
identified a few nucleotides upstream of the TATA sequence (Fig.
2A), thus supporting the hypothesis that the region
we had isolated contained the core promoter and part of the regulatory
region of the human Phox2a gene. To confirm this at a
functional level, we cloned the PstI-NcoI
fragment in front of the luciferase reporter gene and performed
transient transfections in the SY5Y human neuroblastoma cell line. The
construct showed as much as 25× the activity of the promoterless
pGL3basic and worked slightly more than the plasmid SV40 that contains
the SV40 viral promoter (Fig.
4B).

View larger version (10K):
[in this window]
[in a new window]
|
Figure 4.
Functional mapping and characterization of the
Phox2a minimal promoter. A, Schematic representation of
the PstI/NcoI and
SacI/EagI constructs. The
striped box indicates the DNA sequence specifying the 5'
UTR of the mRNA; the black region corresponds to the
first part of the coding sequence, and the ATG marks the
start codon. The arrow indicates the transcription start
site. The relevant restriction sites are shown. The
Firefly luciferase reporter gene (luc) is
represented as an open box. The sequence in the
enlargement above corresponds to the
SacI-EagI region. The putative TATA box
and Sp1 site are indicated, with the nucleotide substitutions
introduced by recombinant PCR shown above. pGL3basic and SV40, which
contain no promoter or the viral promoter SV40, were used as negative
or positive controls, respectively. B, Luciferase
assays. SY5Y cells were transiently transfected with the constructs
indicated on the left, and the luciferase assays were
performed 48 hr later. The bars represent the
transcriptional activity of the constructs given as a percentage of the
PstI/NcoI construct. The data represent
the means ± SE (error bars) of at least three independent
experiments performed in duplicate.
|
|
Molecular and functional analysis of the human Phox2a
minimal promoter
To demonstrate that the DNA region of the human Phox2a
gene (previously shown to contain a putative TATA box and a putative Sp1 site) could be engaged in interactions with nuclear proteins, we
performed in vitro footprint experiments. A DNA fragment
corresponding to the StuI-NcoI region was
labeled on the bottom strand, incubated with either SY5Y or HeLa
nuclear extracts, and treated with increasing amounts of DNaseI. As a
negative control, the labeled DNA was digested with no nuclear extract
and in the presence of BSA. These experiments showed that the DNA
region encompassing the putative TATA box and Sp1 cis-acting
elements was completely protected from digestion by both the SY5Y and
HeLa extracts (Fig. 5). To demonstrate
the functional contribution of these DNA elements to the activity of
the Phox2a promoter, we introduced point mutations in the
PstI/NcoI construct and performed transient
transfection experiments in SY5Y (Fig. 4). The mutations in the Sp1 and
TATA box sequences severely affected the activity of the
PstI/NcoI construct: the
PstI/NcoI Sp1mut and
PstI/NcoI TATAmut constructs worked five times
less than the parental plasmid, and the simultaneous mutation of the
two sites completely abolished the transcriptional activity of the
resulting plasmid PstI/NcoI Sp1/TATAmut, the
activity of which was comparable with that of pGL3basic (Fig. 4).
Conversely, the SacI-EagI construct containing
only the Sp1 site, the TATA box, and the initiation of transcription
still retained appreciable transcriptional activity (Fig. 4) (five
times more than that of pGL3basic).

View larger version (43K):
[in this window]
[in a new window]
|
Figure 5.
DNase footprinting of the
StuI-NcoI region. The
StuI-NcoI fragment was labeled on the
bottom strand and digested with increasing amounts of DNaseI in the
presence of SY5Y (lanes 4-6) and HeLa
(lanes 7-9) nuclear extracts. Digestions were also
performed in the presence of BSA as a negative control (lanes
1-3). The enlargement on the right shows the
sequence of the DNA region that was protected from digestion by both
nuclear extracts. The TATA box and Sp1 site are boxed.
On the left is a DNA sequence loaded in parallel as a
molecular marker.
|
|
The DNA-protein interactions on the Sp1 consensus site were further
characterized by EMSA. When a labeled oligonucleotide bearing the
Phox2a Sp1 site was incubated with the SY5Y nuclear extract, four major
retarded complexes were observed (Fig. 6, lane 1). All of these bands were competed by a molar
excess of unlabeled Phox2a Sp1 oligonucleotide, whereas the addition of a mutated Phox2a Sp1 oligonucleotide did not have any effect (Fig. 6,
lane 2-5). A canonical Sp1 binding site was capable of
competing the A, B, and D bands but failed to inhibit a faint band
immediately below the A band (Fig. 6, lane 6,
asterisk) and only partially blocked the formation of the C
complex. Competition with a canonical Egr1 oligonucleotide did not
interfere at all with the formation of the four retarded bands (Fig. 6,
lane 7). Supershift experiments were performed to
confirm the involvement of Sp1 and to reveal the participation of other
members of the Sp family. Antibodies against Sp1, Sp3, and Sp4 were all
capable of inducing the formation of supershifted complexes (Fig. 6,
lanes 8, 9, 10). In particular, band B
was supershifted only by an anti-Sp3 antibody, and complex A was made
of all three Sp proteins. The band immediately below the A band was not
supershifted when antibodies against Sp1, Sp3, and Sp4 were added to
the same sample (Fig. 6, lane 11, asterisk). The
Egr1 antibody induced a very faint supershifted band (Fig. 6,
lane 12), whereas the antibodies against Egr2 and Egr3
failed to shift any complex (Fig. 6, lanes 13,
14).

View larger version (68K):
[in this window]
[in a new window]
|
Figure 6.
Molecular characterization of the Sp1 site in the
human Phox2a minimal promoter by EMSA. EMSAs were performed using a
probe corresponding to a part of the Phox2a minimal promoter (from
nucleotide 71 to 47) that contained the previously characterized
Phox2a Sp1 site. On the left, the arrows
and corresponding letters (A,
B, C, D) indicate four
retarded complexes that formed on incubation of the labeled probe with
the SY5Y nuclear extract (lane 1). Competition
experiments were performed in the presence of a 100× or 1000× excess
of the wild-type oligonucleotide (lanes 2-3) or in the
presence of its mutated version in which the Sp1 site was mutagenized
(lanes 4-5). Competition experiments were also
performed using a 1000× excess of oligonucleotides bearing canonical
sites for Sp1 and Egr1 (lanes 6-7). Supershift
experiments were performed using the 71/ 47 wild-type
oligonucleotide together with the indicated antibodies (lanes
8-14). On the right, the arrows and
corresponding letters (E,
F, G) indicate the supershifted
complexes. The asterisks mark a band that migrated
immediately below the A complex (lanes 6 and
11). The free probe is indicated.
|
|
Functional role of the DNA regions surrounding the
minimal promoter
Comparison of the transcriptional activities of the
PstI/NcoI and SacI/EagI
constructs (Fig. 4B) clearly indicated that the DNA
regions surrounding the minimal promoter played a fundamental role in
the expression of Phox2a. A more detailed deletion analysis of the
PstI-NcoI region in both SY5Y and HeLa cells
revealed the presence of two functionally relevant subregions. The
first corresponded to the PstI-StuI fragment,
and its deletion produced a fivefold reduction in the expression of the
reporter gene in SY5Y (Fig. 7B, compare
constructs Pst/NcoI and StuI/NcoI),
whereas the same deletion led to a modest increase in transcriptional
activity in HeLa cells. A further deletion of the
StuI-SacI fragment had negligible effects on the
expression of the luciferase gene in both cell lines (Fig.
7B, compare constructs StuI/NcoI and
SacI/NcoI). The PstI-StuI
subregion therefore seemed to contain one or more elements that
activated transcription only in neuroblastoma cells. The second
subregion corresponded to most of the DNA region specifying the 5' UTR
of the mRNA. Its replacement with the 5' UTR of the luciferase gene
produced a fivefold increase in luciferase gene expression only in HeLa
cells (Fig. 7B, compare the constructs PstI/NcoI and PstI/EagI).
This suggested that the EagI-NcoI region contained one or more elements that negatively regulate the expression of the reporter gene in non-neuronal cells. In principle, these elements may act at either a transcriptional or
post-transcriptional level, or both. In brief, the
PstI-NcoI region seems to contain negative and
positive cis-acting elements that restrict the activity of
the human Phox2a promoter to neuroblastoma cells. In this study, we
focused on the positive mechanisms that take place in neuronal cells.

View larger version (14K):
[in this window]
[in a new window]
|
Figure 7.
Functional characterization of the 5' regulatory
region of the human Phox2a gene. A,
Schematic representation of the reporter constructs used in the
transient transfection experiments. The striped box
indicates the DNA sequence specifying the 5' UTR of the mRNA; the
black region corresponds to the first part of the coding
sequence, and the ATG marks the start codon. The
arrow indicates the transcription start site. The
relevant restriction sites are shown. The Firefly
luciferase reporter gene (luc) is represented as an
open box. B, Luciferase assays. SY5Y and
HeLa cells were transiently transfected with the constructs indicated
on the left, and the luciferase assays were performed 48 hr later. The bars represent the transcriptional
activity of the constructs given as a percentage of the activity of the
PstI/NcoI construct. The data represent
the means ± SE (error bars) of at least three independent
experiments performed in duplicate.
|
|
Regulation of the human Phox2a 5' regulatory region
by homeoproteins
The PstI-StuI region contains a putative
DNA binding site for homeoproteins (Fig. 2). To investigate whether
this site could account for at least part of the positive
transcriptional effects that this region exerted in neuroblastoma
cells, we introduced three point mutations into the putative
homeoprotein core sequence and transfected the resulting
PstI/NcoI hbsmut construct into SY5Y cells. In
comparison with its wild-type counterpart, this construct showed a
dramatic decrease in the capability of driving the expression of the
reporter gene, having a transcriptional activity that was similar to
that of pGL3basic (Fig.
8A). When these
constructs were transfected into HeLa cells, the decrease in
transcriptional activity was only 50% (Fig.
9, compare the PstI/NcoI and PstI/NcoI
hbsmut constructs when cotransfected with the empty pCDNA3 vector; and
data not shown). In line with these results, an identical mutation of
the hbs in the context of the PstI/EagI plasmid,
the most active construct in HeLa cells, produced a similar decrease in
transcriptional activity (data not shown).

View larger version (22K):
[in this window]
[in a new window]
|
Figure 8.
Functional and molecular characterization of the
putative homeoprotein binding site (hbs).
A, Luciferase assays. SY5Y cells were transiently
transfected with the constructs indicated on the left,
and the luciferase assays were performed 48 hr later. The
bars represent the transcriptional activity of the
constructs given as the percentage of the activity of the
PstI/NcoI construct. The data represent
the means ± SE (error bars) of at least three independent
experiments performed in duplicate. B, EMSAs were
performed using a probe corresponding to the human Phox2a sequence
between the nucleotides 363 and 337 (Fig. 2), which contained the
putative homeoprotein binding site. On the left, the
arrows and corresponding letters
(A, B, C) indicate the
retarded complexes that formed on incubation of the labeled probe with
the SY5Y nuclear extract (lane 1). Competition
experiments were performed in the presence of a 1000× excess of the
wild-type oligonucleotide (lane 2) or in the presence of
its mutated version in which the putative homeoprotein binding site was
mutagenized (lane 3). The specificity of the
DNA-protein interactions was also checked by means of competition with
a cold oligonucleotide bearing the Phox2 site of the
dopamine- -hydroxylase gene (Yang et
al., 1998 ) (lane 4). On the right,
the arrows and corresponding letters
(D, E) indicate the supershifted
complexes obtained using an antibody directed against Phox2b (Pattyn et
al., 1997 ) (lane 5). Lane 6, No nuclear
extract.
|
|

View larger version (24K):
[in this window]
[in a new window]
|
Figure 9.
Transactivation of the human Phox2a promoter by
Phox2b. Luciferase assays were performed to measure the activity of the
Phox2a promoter reporter constructs upon their cotransfection in HeLa
cells with the pCDNA3 expression vector harboring the Phox2b cDNA or
with the empty vector. The bars represent the
transcriptional activity of the constructs (indicated on the
left) given as a percentage of the activity of the
PstI/NcoI construct when cotransfected
with the empty pCDNA3. The data represent the means ± SE (error
bars) of at least three independent experiments performed in duplicate.
5 indicates the 1011/+180 construct described in
Flora et al. (2000) , which corresponds to part of the promoter region
of the human 5 nicotinic subunit gene.
|
|
To demonstrate that the putative homeoprotein DNA binding site was
capable of binding nuclear proteins, we performed gel-shift assays.
When a labeled oligonucleotide corresponding to the Phox2a sequence
that included the putative homeoprotein binding site was incubated with
a SY5Y nuclear extract, three distinct retarded bands were observed,
all of which were competed by a molar excess of cold oligonucleotide
(Fig. 8B). On the contrary, a cold mutagenized oligonucleotide bearing the same mutations as those tested in the
transfection experiments was unable to compete. Genetic evidence in
mice indicates that Phox2a could be regulated by Phox2b, and so we
performed competition experiments using a cold oligonucleotide containing the previously characterized Phox2 Responsive Sequence 1 (PRS1) of the dopamine- -hydroxylase gene
promoter (Yang et al., 1998 ). As shown in Figure 8B
(lane 4), a molar excess of this oligonucleotide
greatly reduced the formation of the three retarded bands. A more
direct demonstration of the involvement of Phox2b in the observed
gel-retardation pattern was provided by supershift experiments. When a
previously characterized polyclonal antibody directed against Phox2b
(Pattyn et al., 1997 ) was added to a reaction containing the SY5Y
nuclear extract and the wild-type Phox2a hbs oligonucleotide, two
additional ultra-retarded bands were observed (Fig.
8B, lane 5).
Transactivation of the human Phox2a promoter by Phox2b
To obtain further functional evidence concerning the role of
Phox2b in the expression of Phox2a, we performed
cotransfection experiments in which a vector expressing Phox2b was
introduced into HeLa cells together with different Phox2a reporter
constructs (Fig. 9). A considerable transactivation was observed with
the wild-type PstI/NcoI reporter construct, but,
surprisingly, both the PstI/NcoI hbsmut and the
StuI/NcoI constructs, which lacked the
homeoprotein binding site, were partially transactivated in the
presence of Phox2b. This partial response did not seem to be caused by
an aspecific effect of Phox2b, because the regulatory region of the
human 5 gene [construct 1011/+180 (Flora et al., 2000 )], a
cholinergic-nicotinic subunit that is normally expressed in HeLa cells,
was not transactivated at all.
 |
DISCUSSION |
In this study, we started delineating the transcriptional
mechanisms underlying the expression of the human Phox2a
gene in neuronal cells. Using molecular and functional criteria, we
first identified the minimal promoter of the gene, the activity of
which was found to rely on a degenerate TATA box and a canonical Sp1 site.
Sp1 is a ubiquitous protein that belongs to the superfamily of
mammalian Sp/XKLF transcription factors, which consists of at least 16 different members (Philipsen and Suske, 1999 ). The most characterized
subfamily is that of Sp1, Sp2, Sp3, and Sp4, which, with the exception
of Sp2, preferentially bind to GC-rich elements identical to that
identified in the human Phox2a promoter. Supershift experiments showed
that all three transcription factors can bind to the Phox2a GC box.
Because of their very similar affinity for the same DNA binding site,
the significance of the coexpression of these three factors is not
fully understood; however, it is worth noting that, under certain
circumstances and as a result of competition, Sp3 and Sp4 can act as
repressors of Sp1-activated transcription (Hagen et al., 1994 ; Majello
et al., 1995 ; Kwon et al., 1999 ), and that the cell content of the
three proteins can vary under different conditions, including
proliferation and differentiation (Apt et al., 1996 ). At the level of
the Phox2a promoter, this picture seems to be even more complicated
because the Egr1 transcription factor appears to bind to the same
region (although this needs to be confirmed by more directed
experiments), and under certain circumstances, Egr1 can also interfere
with Sp1-mediated transcription by competing for the same DNA site (Ebert and Wong, 1995 ). Both the competition and supershift data showed
that, when the binding of all of the members of the Sp-family was
prevented, a novel band appeared that could not be supershifted by the
Egr1 antibody (data not shown). This band may simply reflect the
binding of a nonspecific factor that binds the site with low affinity
under these artificial conditions, or the binding of a non-Sp member of
the Sp/XKLF superfamily. Taken together, these observations allow us to
speculate that several levels of transcriptional control may exist at
the human Phox2a promoter, most of which rely on the same DNA site.
Experiments using HeLa cells gave very similar results (data not
shown), except for Sp4, the interaction of which with the GC box in the
Phox2a promoter was not detected (data not shown). This finding was
expected because Sp4 is expressed much more in neuronal tissues
(Philipsen and Suske, 1999 ), and, consistently, this distribution
pattern is reproduced in neuroblastoma and HeLa cells (data not shown).
However, the presence or less of the Sp4 binding did not apparently
modify the function of the minimal promoter, which showed very similar
transcriptional activity in both SY5Y and HeLa cells (data not shown).
This suggested that the elements responsible for the neurospecific
expression of the gene lie outside of this region.
We therefore studied the DNA regions immediately upstream and
downstream of the core promoter and identified two subregions that have
different effects in neuronal and non-neuronal cell lines. The first
largely coincides with the part of the Phox2a gene
specifying the 5' UTR of the mRNA and contains one or more reducer
elements that repress gene expression only in HeLa cells. The molecular
characterization of this subregion will be described elsewhere, and we
shall here concentrate on the upstream PstI-StuI region, which seemed to contain one (or more) positive neurospecific elements, because its deletion caused a considerable decline in luciferase expression only in SY5Y cells.
Computer-assisted analysis revealed that this DNA fragment contained a
putative homeoprotein binding site. It has been shown that the
homeoproteins involved in the development of the nervous system can
sometimes regulate each other by creating complex transcriptional networks (Briscoe et al., 2000 ). The mutation of the Phox2a/hbs severely affected the transcriptional activity of the
PstI/NcoI construct in SY5Y, thus indicating that
this site is necessary for the expression of Phox2a in this
cellular context. It has been shown previously in KO mice that, during
the development of most of the autonomic nervous system, Phox2a seems
to act downstream of the highly homologous homeodomain protein Phox2b
(Morin et al., 1997 ; Pattyn et al., 1997 , 1999 ; Dubreuil et al., 2000 ). The human Phox2b protein (also known as PMX2B) shares with its mouse
ortholog an amino acid identity of 99% and an identical homeodomain,
which is responsible for the interaction with DNA. The results of our
EMSA and supershift experiments provide the first molecular evidence
that Phox2b/PMX2b is capable of specifically interacting with the human
Phox2a promoter. To show that it also plays a functional role in
Phox2a expression, we performed cotransfection experiments
in HeLa cells (which do not express any endogenous Phox2a or Phox2b)
that clearly demonstrated the ability of Phox2b to transactivate the
Phox2a promoter in a specific way, because it did not affect a control
promoter. Phox2b still retained some transactivating activity on the
Phox2a promoter even when its cognate DNA binding site was deleted or
mutated. We hypothesize that Phox2b, regardless of DNA binding, can
contact one or more components of the transcriptional apparatus that
assembles at the human Phox2a core promoter, although such interactions
are more stable and efficacious when Phox2b is also bound to DNA. This
would be in line with the observation that Drosophila fushi tarazu is still capable of activating some of its target genes even in the absence of its DNA binding domain (Copeland et al., 1996 ).
Taken together, these data suggest that the direct interaction with the
cognate cis-acting element is to some extent dispensable for
some homeodomain proteins.
In conclusion, we propose that the expression of the human
Phox2a gene primarily relies on a minimal promoter that
potentially has several levels of regulation, perhaps also in response
to external stimuli as suggested by the possible involvement of Egr1. The basal activity of this minimal promoter needs to be stimulated but
also restricted to neuronal tissues, particularly to various structures
of the autonomic nervous system. This seems to be achieved by combining
positive and negative mechanisms that act in neuronal and non-neuronal
contexts, respectively. We studied the positive mechanisms and found
that Phox2b is one of the major players in the expression of Phox2a.
This is the first study to provide information concerning the molecular
events underlying the expression of a fundamental specifier of the
human sympathetic neuron phenotype. This approach complements in
vivo studies and will lead to a better understanding of how
neuronal cell fate is established.
Note added in proof. The sequence of the
PHOX2a gene promoter is available at EMBL Nucleotide
Sequence Database under Accession no. AJ320270.
 |
FOOTNOTES |
Received Feb. 22, 2001; revised June 4, 2001; accepted July 10, 2001.
This work was supported in part by grants to Francesco Clementi from
the Italian Ministry of University and Scientific and Technological
Research (MURST Grant MM05152538) and from the European "Training and
Mobility of Researchers" Program (Contract ERB4061PL97-0790). We
thank Kevin Smart for his help in preparing this manuscript and Susanna
Terzano for suggestions.
Correspondence should be addressed to Dr. Diego Fornasari, Department
of Medical Pharmacology, University of Milan, Consigilo Nazionale delle
Ricerche Cellular and Molecular Pharmacology Center, Via Vanvitelli 32, 20129 Milano, Italy. E-mail:
D.Fornasari{at}csfic.mi.cnr.it.
 |
REFERENCES |
-
Anderson DJ
(1997)
Cellular and molecular biology of neural crest cell lineage determination.
Trends Genet
13:276-280[Web of Science][Medline].
-
Apt D,
Watts RM,
Suske G,
Bernard Hu
(1996)
High Sp1/Sp3 ratios in epithelial cells during epithelial differentiation and cellular transformation correlate with the activation of the HPV-16 promoter.
Virology
224:281-291[Web of Science][Medline].
-
Battaglioli E,
Gotti C,
Terzano S,
Flora A,
Clementi F,
Fornasari D
(1998)
Expression and transcriptional regulation of the human alpha3 neuronal nicotinic receptor subunit in T lymphocyte cell lines.
J Neurochem
71:1261-1270[Medline].
-
Briscoe J,
Pierani A,
Jessel TM,
Ericson J
(2000)
A homeodomain code specifies progenitor cell identity and neuronal fate in the ventral neural tube.
Cell
101:435-445[Web of Science][Medline].
-
Copeland JWR,
Nasiadka A,
Dietrich BH,
Krause HM
(1996)
Patterning of the Drosophila embryo by a homeodomain-deleted Ftz polypeptide.
Nature
379:162-165[Medline].
-
Dubreuil V,
Hirsch MR,
Pattyn A,
Brunet JF,
Goridis C
(2000)
The Phox2b transcription factor coordinately regulates neuronal cell cycle exit and identity.
Development
127:5191-5201[Abstract].
-
Durbec PL,
Larsson-Blomberg LB,
Schuchardt A,
Costantini F,
Pachnis V
(1996)
Common origin and developmental dependence on c-ret of subsets of enteric and sympathetic neuroblasts.
Development
122:349-358[Abstract].
-
Ebert SN,
Wong DL
(1995)
Differential activation of the rat phenylethanolamine N-methyltransferase gene by Sp1 and Egr-1.
J Biol Chem
270:17299-17305[Abstract/Free Full Text].
-
Flora A,
Schulz R,
Benfante R,
Battaglioli E,
Terzano S,
Clementi F,
Fornasari D
(2000)
Neuronal and extra-neuronal regulation of the expression of the human alpha5 nicotinic receptor subunit gene.
J Neurochem
75:18-27[Medline].
-
Francis NJ
(1999)
Cellular and molecular determinants of sympathetic neuron development.
Annu Rev Neurosci
22:541-566[Web of Science][Medline].
-
Goridis C,
Brunet J
(1999)
Transcriptional control of neurotransmitter phenotype.
Curr Opin Neurobiol
9:47-53[Web of Science][Medline].
-
Gotti C,
Fornasari D,
Clementi F
(1997)
Human neuronal nicotinic receptors.
Prog Neurobiol
53:199-237[Web of Science][Medline].
-
Hagen G,
Muller S,
Beato M,
Suske G
(1994)
Sp-1 mediated transcriptional activation is repressed by Sp3.
EMBO J
13:3843-3851[Web of Science][Medline].
-
Higuchi R
(1990)
Recombinant PCR.
In: PCR protocols (Michael AI,
ed), pp 169-176. San Diego: Academic.
-
Hirsch M,
Tiveron M,
Guillemot F,
Brunet J,
Goridis C
(1998)
Control of noradrenergic differentiation and Phox2a expression by MASH1 in the central and peripheral nervous system.
Development
125:599-608[Abstract].
-
Johnson KR,
Smith L,
Johnson DK,
Rhodes J,
Rinchik EM,
Thayer M,
Lewis EJ
(1996)
Mapping of the ARIX homeodomain gene to mouse chromosome 7 and human chromosome 11q13.
Genomics
33:527-531[Web of Science][Medline].
-
Kwon HS,
Kim MS,
Edenberg HJ,
Hur MW
(1999)
Sp3 and Sp4 can repress transcription by competing with Sp1 for the core cis-elements on the human ADH5/FDH minimal promoter.
J Biol Chem
274:20-28[Abstract/Free Full Text].
-
Lo L,
Sommer L,
Anderson DJ
(1997)
MASH1 maintains competence for BMP2-induced neuronal differentiation in post-migratory neural crest cells.
Curr Biol
7:440-450[Web of Science][Medline].
-
Lo L,
Tiveron M,
Anderson D
(1998)
MASH1 activates expression of the paired homeodomain transcription factor Phox2a, and couples pan-neuronal and subtype-specific components of autonomic neuronal identity.
Development
125:609-620[Abstract].
-
Majello B,
De Luca P,
Suske G,
Lania L
(1995)
Differential transcriptional regulation of c-myc promoter through the same DNA binding sites targeted by Sp1-like proteins.
Oncogene
10:1841-1848[Web of Science][Medline].
-
Morin X,
Cremer H,
Hirsch M,
Kapur RP,
Goridis C,
Brunet J
(1997)
Defects in sensory and autonomic ganglia and absence of locus coeruleus in mice deficient for the homeobox gene Phox2a.
Neuron
18:411-423[Web of Science][Medline].
-
Pattyn A,
Morin X,
Cremer H,
Goridis C,
Brunet J
(1997)
Expression and interactions of the two closely related homeobox genes Phox2a and Phox2b during neurogenesis.
Development
124:4065-4075[Abstract].
-
Pattyn A,
Morin X,
Cremer H,
Goridis C,
Brunet J
(1999)
The homeobox gene Phox2b is essential for the development of autonomic neural crest derivatives.
Nature
399:366-370[Medline].
-
Philipsen S,
Suske G
(1999)
A tale of three fingers: the family of mammalian Sp/XKLF transcription factors.
Nucleic Acids Res
27:2991-3000[Abstract/Free Full Text].
-
Stanke M,
Junghans D,
Geissen M,
Goridis C,
Ernsberger U,
Rohrer H
(1999)
The Phox2 homeodomain proteins are sufficient to promote the development of sympathetic neurons.
Development
126:4087-4094[Abstract].
-
Terzano S,
Flora A,
Clementi F,
Fornasari D
(2000)
The minimal promoter of the human alpha3 nicotinic receptor subunit gene. Molecular and functional characterization.
J Biol Chem
275:41495-41503[Abstract/Free Full Text].
-
Tiveron M,
Hirsch M,
Brunet J
(1996)
The expression pattern of the transcription factor Phox2 delineates synaptic pathways of the autonomic nervous system.
J Neurosci
16:7649-7660[Abstract/Free Full Text].
-
Valarché I,
Tissier-Seta J,
Hirsch M,
Martinez S,
Goridis C,
Brunet J
(1993)
The mouse homeodomain protein Phox2 regulates Ncam promoter activity in concert with Cux/CDP and is a putative determinant of neurotransmitter phenotype.
Development
119:881-896[Abstract].
-
Yang C,
Kim H,
Seo H,
Kim C,
Brunet J,
Kim K
(1998)
Paired-like homeodomain proteins, Phox2a and Phox2b are responsible for noradrenergic cell-specific transcription of the dopamine
-hydroxylase gene.
J Neurochem
71:1813-1826[Web of Science][Medline]. -
Young HM,
Hearn CJ,
Ciampoli D,
Southwell BR,
Brunet JF,
Newgreen DF
(1998)
A single rostro-caudal colonisation of the rodent intestine by enteric neuron precursors is revealed by the expression of Phox2b, Ret and p75, and by explants grown under the kidney capsule or in organ culture.
Dev Biol
202:67-84[Web of Science][Medline].
-
Zellmer E,
Zhang Z,
Greco D,
Rhodes J,
Cassel S,
Lewis EJ
(1995)
A homeodomain protein selectively expressed in noradrenergic tissue regulates transcription of neurotransmitter biosynthetic genes.
J Neurosci
15:8109-8120[Abstract].
Copyright © 2001 Society for Neuroscience 0270-6474/01/21187037-09$05.00/0
This article has been cited by other articles:

|
 |

|
 |
 
A. Flora, J. J. Garcia, C. Thaller, and H. Y. Zoghbi
The E-protein Tcf4 interacts with Math1 to regulate differentiation of a specific subset of neuronal progenitors
PNAS,
September 25, 2007;
104(39):
15382 - 15387.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Benfante, A. Flora, S. Di Lascio, F. Cargnin, R. Longhi, S. Colombo, F. Clementi, and D. Fornasari
Transcription Factor PHOX2A Regulates the Human {alpha}3 Nicotinic Receptor Subunit Gene Promoter
J. Biol. Chem.,
May 4, 2007;
282(18):
13290 - 13302.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Moriguchi, N. Takako, M. Hamada, A. Maeda, Y. Fujioka, T. Kuroha, R. E. Huber, S. L. Hasegawa, A. Rao, M. Yamamoto, et al.
Gata3 participates in a complex transcriptional feedback network to regulate sympathoadrenal differentiation
Development,
October 1, 2006;
133(19):
3871 - 3881.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. Cargnin, A. Flora, S. D. Lascio, E. Battaglioli, R. Longhi, F. Clementi, and D. Fornasari
PHOX2B Regulates Its Own Expression by a Transcriptional Auto-regulatory Mechanism
J. Biol. Chem.,
November 11, 2005;
280(45):
37439 - 37448.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Bachetti, I. Matera, S. Borghini, M. D. Duca, R. Ravazzolo, and I. Ceccherini
Distinct pathogenetic mechanisms for PHOX2B associated polyalanine expansions and frameshift mutations in congenital central hypoventilation syndrome
Hum. Mol. Genet.,
July 1, 2005;
14(13):
1815 - 1824.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y Jiang, T Matsuo, H Fujiwara, S Hasebe, H Ohtsuki, and T Yasuda
ARIX gene polymorphisms in patients with congenital superior oblique muscle palsy
Br. J. Ophthalmol.,
February 1, 2004;
88(2):
263 - 267.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
V. Dubreuil, M.-R. Hirsch, C. Jouve, J.-F. Brunet, and C. Goridis
The role of Phox2b in synchronizing pan-neuronal and type-specific aspects of neurogenesis
Development,
March 13, 2003;
129(22):
5241 - 5253.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|